Alzheimer's Drug Discovery Foundation offers Multiple Funding Opportunities

The Alzheimer's Drug Discovery Foundation has released several Requests for Proposals for research and clinical trial programs related to Alzheimer's disease, other dementias and cognitive aging. Letters of Intent are due June 2, 2015. Full applications are due June 16, 2015.

The UNC Office of Corporate and Foundation Relations has identified the following private funding opportunity/opportunities:

 Alzheimer's Drug Discovery Foundation:

Foundation web site: http://www.alzdiscovery.org/

The ADDF/Belfer ApoE Therapeutics Innovation Program
Awards up to $1,000,000

Program funds up to $300,000 for up to two (2) years per application for pre-clinical programs and up to $1,000,000 per application for clinical trials of novel agents such as phase 1b or 2a employing biomarkers as outcome measures. Funding goes to projects that accelerate the development of novel therapeutics designed to target apoE pathological mechanisms.

Letters of Intent are due two (2) weeks before application deadline.

Application Guidelines: http://www.alzdiscovery.org/assets/content/static/2015_ApoE_RFP.pdf


2015 Preclinical Drug Discovery Program

Awards up to $15,000 per year 

Program attempts to fill the critical translational funding gap between basic research and alter stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer’s disease, other dementias and cognitive aging. Funding priorities include drug discovery and biomarker development. Funding mechanisms:

  • Academic program to create and support innovative translational programs in academic medical centers and universities
  • Biotechnology development program supports qualified scientific projects in existing, private, early-stage biotechnology companies. (Typically made as program-related investment)
  • Biotechnology Founders Technology Transfer Program supports academic programs eligible for technology transfer and the start-up of new biotechnology companies. 

Application Guidelines: http://www.alzdiscovery.org/assets/content/static/2015_Preclinical_Drug_Discovery_RFP_final.pdf


2015 Program to Accelerate Clinical Trials (PACT) Program
Awards up to $1,500,000 per application

Program’s goal is to increase the number of innovative treatments tested in humans for Alzheimer’s disease, related dementias and cognitive aging. Multiyear proposals will be considered. Program will fund biomarker-based pilot clinical trials for Alzheimer’s disease and in some cases will also support Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. ADDF is also interested in supporting clinical biomarker development programs and biomarker-based trials to validate putative mechanisms of action for targeted pharmacological and non-pharmacological approaches to intervention. This program follows the same funding mechanisms described in the 2015 Preclinical Drug Discovery Program identified above. Particular funding interests include:

  • Repurposing – testing drugs approved for other Alzheimer’s disease clinical trials; proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases
  • Therapies addressing the following targets: energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface

Application Guidelines: http://www.alzdiscovery.org/assets/content/static/2015_PACT_RFP_final.pdf

The UNC Office of Corporate and Foundation Relations is available to provide assistance in pursuing privately funded opportunities. Email cfr@unc.edu or phone 919.962.3423. 

Filed under: